Charles G. Phillips III has been a director of Novocure since 2012 and has served on our audit committee and as the chairperson of our compensation committee since 2012. From 2008 to 2011, Mr. Phillips served as Chief Operating Officer of Prentice Capital Management, LLC, a private investment management firm. Previously, Mr. Phillips was a managing director from 1991 to 2002 and President from 1998 to 2001 of Gleacher & Co. , an investment banking and management firm. Prior to joining Gleacher & Co., Mr. Phillips held senior positions at other leading investment banking firms, including nine years at Morgan Stanley, where he served as a managing director within the investment banking division and founded the firm’s high-yield finance activities. Mr. Phillips has served on the boards of several public and private companies and private investment funds, including California Pizza Kitchen, Inc. and Fidus Investment Corporation, and he has also served on the governing bodies of a number of educational and non-profit organizations. Mr. Phillips earned an A.B. from Harvard College and an M.B.A from Harvard Business School.
clinical trialsOur mechanism of action is broadly applicable across a variety of solid tumors.
novocuretrial.comThe science of Tumor Treating Fields extends beyond glioblastoma. We are conducting clinical trials in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and mesothelioma.